Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus Dose Escalation in Metastatic Breast Cancer
NCT02387099Phase 2Completed
- Sponsor
- GBG Forschungs
- Start
- May 2015
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of everolimus in Hormone-Receptor-Positive Breast Cancer, sponsored by GBG Forschungs. Started May 2015; status: completed.
02
Drugs
everolimus
03
Conditions
Hormone-Receptor-Positive Breast Cancer
Beyond the preview
Go deeper on NCT02387099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02387099.